72.40
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Bio Techne Corp stock is traded at $72.40, with a volume of 2.01M.
It is up +0.32% in the last 24 hours and up +1.64% over the past month.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
See More
Previous Close:
$72.17
Open:
$72.23
24h Volume:
2.01M
Relative Volume:
0.43
Market Cap:
$11.28B
Revenue:
$1.21B
Net Income/Loss:
$109.52M
P/E Ratio:
103.99
EPS:
0.6962
Net Cash Flow:
$269.60M
1W Performance:
+0.15%
1M Performance:
+1.64%
6M Performance:
+20.81%
1Y Performance:
+34.72%
Bio Techne Corp Stock (TECH) Company Profile
Name
Bio Techne Corp
Sector
Industry
Phone
612-379-8854
Address
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Compare TECH vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
TECH
Bio Techne Corp
|
72.40 | 11.25B | 1.21B | 109.52M | 269.60M | 0.6962 |
|
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
|
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Aug-21-25 | Upgrade | Citigroup | Neutral → Buy |
| Jul-22-25 | Resumed | Stephens | Overweight |
| Jul-09-25 | Initiated | TD Cowen | Buy |
| May-30-25 | Initiated | Wells Fargo | Overweight |
| Apr-09-25 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Mar-18-25 | Initiated | Evercore ISI | Outperform |
| Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-22-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-08-24 | Initiated | Scotiabank | Sector Outperform |
| Feb-02-24 | Downgrade | Stifel | Buy → Hold |
| Dec-07-23 | Initiated | UBS | Buy |
| Aug-28-23 | Initiated | William Blair | Outperform |
| Jan-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Sep-15-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-08-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Feb-23-21 | Upgrade | Stifel | Hold → Buy |
| Jan-25-21 | Reiterated | The Benchmark Company | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Jul-15-20 | Downgrade | Stephens | Overweight → Equal-Weight |
| May-27-20 | Downgrade | Stifel | Buy → Hold |
| May-14-20 | Initiated | The Benchmark Company | Buy |
| Jan-08-20 | Resumed | Stephens | Overweight |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Nov-15-19 | Initiated | Stifel | Buy |
| Jul-02-19 | Upgrade | Janney | Neutral → Buy |
| Jan-14-19 | Upgrade | Stephens | Equal-Weight → Overweight |
| Oct-31-18 | Downgrade | Craig Hallum | Buy → Hold |
| Oct-17-18 | Initiated | Goldman | Neutral |
| Jun-15-18 | Initiated | Argus | Buy |
| Jul-13-17 | Initiated | Wells Fargo | Market Perform |
| Feb-09-17 | Initiated | Citigroup | Buy |
| Jan-18-17 | Initiated | Deutsche Bank | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Jan-21-15 | Reiterated | Robert W. Baird | Outperform |
| Sep-20-13 | Upgrade | Robert W. Baird | Neutral → Outperform |
View All
Bio Techne Corp Stock (TECH) Latest News
Bio-Techne Corp (TECH) Stock News Today - tradingkey.com
Wells Fargo Initiates Bio-Techne(TECH.US) With Hold Rating, Announces Target Price $73 - Moomoo
Bio-Techne (NASDAQ:TECH) Downgraded to Equal Weight Rating by Wells Fargo & Company - MarketBeat
Bio-Techne (NASDAQ:TECH) Dividend Move Sparks Fresh Attention - Kalkine Media
TECH Q4 Earnings Meet Estimates, Revenues Surpass, Stock Rises - TradingView
Bio-Techne Corp (NASDAQ:TECH) to Issue Dividend Increase$0.65 Per Share - MarketBeat
Bio-Techne Corrects Dividend Announcement - Yahoo Finance
Bio-Techne Corp to Issue Quarterly Dividend of $0.08 (NASDAQ:TECH) - MarketBeat
Bio-Techne (NASDAQ:TECH) Releases Earnings Results, Meets Estimates - MarketBeat
Bio-Techne Announces Q4 and Full Fiscal Year 2026 Financial Results Alongside Cash Dividend Declaration - Kalkine Media
Bio-Techne Q4 Results: Sales rise 1.33% YoY, beat estimates - scanx.trade
Bio-Techne Releases Fourth Quarter Fiscal 2026 Results - Investing News Network
TECH Looks 1.1% Undervalued on GF Value™ Amid High P/E and Mixed Guru Activity - GuruFocus
Techne (TECH) Q4 Earnings Meet Estimates - Yahoo Finance
Bio-Techne (NASDAQ:TECH) Surprises With Q2 CY2026 Sales - Yahoo Finance
Bio-Techne earnings matched, revenue topped estimates By Investing.com - Investing.com South Africa
Bio-Techne beats revenue estimates on research, diagnostics demand uptick - finance.yahoo.com
Bio-Techne earnings matched, revenue topped estimates - Investing.com
Bio-Techne declares $0.08 quarterly dividend - Investing.com
Form 8K Bio-Techne Corp For: 12 August By Investing.com - Investing.com Australia
Is Bio-Techne Corp (TECH) Undervalued After Q4 Earnings Beat? GA - GuruFocus
Bio-Techne reports in-line Q4 earnings, beats on revenue - Investing.com
Bio-Techne reports in-line Q4 earnings, beats on revenue By Investing.com - Investing.com India
Bio-Techne Q4 FY2026 earnings: Organic revenue grows 3% as adjusted EPS slips - tradingkey.com
Bio-Techne Q4 Revenue Rises to $321.2 Million - Quiver Quantitative
Bio-Techne Declares Dividend - finance.yahoo.com
Bio-Techne Corp $TECH Stake Decreased by Bank of America Corp DE - MarketBeat
Bio-Techne (TECH) accepts $73-per-share all-cash buyout from Merck KGaA - Stock Titan
Bio-Techne faces quarterly earnings test with Merck deal pending By Investing.com - Investing.com UK
Bio-Techne faces quarterly earnings test with Merck deal pending - Investing.com
Bio-Techne (NASDAQ:TECH) Reaches New 12-Month HighShould You Buy? - MarketBeat
Bio-Techne Corp (TECH) Stock Analysis: Navigating an 11 Billion Dollar Market Cap Amid Modest Growth Challenges - DirectorsTalk Interviews
Bio-Techne Corp (TECH) Stock Analysis & Forecast - tradingkey.com
Is Bio-Techne (TECH) Above Fair Value After A 44% Return? - Yahoo Finance
Amundi Sells 148,342 Shares of Bio-Techne Corp $TECH - MarketBeat
The Manufacturers Life Insurance Company Sells 39,950 Shares of Bio-Techne Corp $TECH - MarketBeat
Investor Trust in Bio-Techne Corp. (TECH) Rises with Easing Headwinds - AlphaStreet
FMR LLC discloses 8.1% Bio-Techne Corp (TECH) holding in amended 13G - Stock Titan
Investors’ Confidence in Bio-Techne Corp. (TECH) Strengthens as Headwind Eases - Yahoo Finance
California State Teachers Retirement System Grows Holdings in Bio-Techne Corp $TECH - MarketBeat
Bio-Techne Corp (TECH) Stock Analysis: Exploring Growth Potential Amidst Analyst Consensus - DirectorsTalk Interviews
Bio-Techne Corp $TECH Shares Sold by Segall Bryant & Hamill LLC - MarketBeat
Form 4 Bio-Techne Corp For: 31 July By Investing.com - Investing.com Nigeria
Bio-Techne Corp (TECH) CFO exercises 62,068 options, 51,024 shares withheld - Stock Titan
BIO-TECHNE Corp (NASDAQ: TECH) CEO exercises 35,000 options, 28,686 shares withheld - Stock Titan
Bio-Techne's Q4 Earnings on Deck: What's in Store for the Stock? - TradingView
Dimensional Fund Advisors LP Boosts Holdings in Bio-Techne Corp $TECH - MarketBeat
Bio-Techne Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Bio-Techne (NASDAQ:TECH) Sets New 52-Week HighShould You Buy? - MarketBeat
Bio-Techne Corp (TECH) SVP option exercise and share withholding - Stock Titan
Bio-Techne Corp (TECH) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bio Techne Corp Stock (TECH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):